- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03898804
An Early Feasibility Study of the ReHAB System (ReHAB)
An Early Feasibility Study to Assess the Effects of the "Reconnecting the Hand and Arm to the Brain (ReHAB)" System
The purpose of this research study is to examine the feasibility of a system that involves implanting small electrodes in the parts of the brain that control movement and sensation, and combining that with electrodes in the upper arm and shoulder to activate paralyzed muscles of the arm and hand. This system is intended for people with extensive paralysis in their arms. The small electrodes in the brain will be used to attempt to measure intended movements, and the muscles in the arm and hand will be stimulated to attempt to follow those intentions.
The study is a prospective, non-randomized, open-label, exploratory safety/feasibility trial of up to 12 subjects. The Primary Endpoint will be evaluation over the first 13 months after implantation, after which the subjects will have the option of removal of the device or continued participation in a long-term study.
Study Overview
Detailed Description
The overall purpose of this trial is to advance development of a novel technological approach to allow individuals with tetraplegia to interact with their environment using their own paralyzed limbs by combining recording of brain activity, brain stimulation to provide sensory feedback, and stimulation of the paralyzed extremities based on neural recordings.
Device Name:
Reconnecting the Hand and Arm to the Brain (ReHAB) System
Intended Use The proposed device is intended to allow greater functional independence for individuals who are paralyzed due to disease or injury. The purpose of this trial is to advance development of a novel technological approach to allow individuals with tetraplegia to interact with their environment using their own paralyzed limbs by combining recording of brain activity, brain stimulation to provide sensory feedback, and stimulation of the paralyzed extremities based on neural recordings.
The target population are individuals with high tetraplegia, defined as less than antigravity weakness of both upper extremities and both lower extremities as a result of an identified and static (stable for at least 3 months) injury or disease affecting upper motor neurons process that prevents motor neural activity from activating muscles below the neck to perform functional activities. Injuries and diseases that lead to this clinical condition include spinal cord injury, and stroke.
Objective(s):
The primary objective of this study is to evaluate the safety, tolerability, and potential efficacy of an approach combining multiple intracortical brain recording/stimulating microarrays with direct peripheral nerve and muscle stimulation for restoration of arm and hand movement in people with high tetraplegia.
Secondary objectives include validation of the combined platform described above as a clinical device to allow paralyzed individuals to have a more meaningful interaction with their environment as assessed by ability to perform brain-controlled reaching and grasping tasks that ultimately might allow for greater functional independence.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jonathan Miller
- Phone Number: (216)844-3470
- Email: jonathan.miller@uhhospitals.org
Study Contact Backup
- Name: Mario Beccera, RN
- Phone Number: 2168441734
- Email: Mario.Becerra@UHhospitals.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- University Hospitals Cleveland Medical Center
-
Contact:
- Jonathan Miller, MD
- Phone Number: 216-844-3470
- Email: Jonathan.Miller@UHhospitals.org
-
Contact:
- Ryan Kneram, RN
- Phone Number: 2162860259
- Email: Ryan.Kneram@UHhospitals.org
-
Principal Investigator:
- Jonathan P Miller, MD
-
Sub-Investigator:
- Robert F Kirsch, PhD
-
Sub-Investigator:
- A. Bolu Ajiboye, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 22 and 65 years of age.
- Tetraplegia due to a static identified disease process (spinal cord injury or stroke) that prevents functional activity of the upper extremity.
- Onset of tetraplegia at least 12 months prior to enrollment, with stability of weakness for at least 3 months.
- Must have sufficiently intact cortical motor structures and stable medical prognoses to be able to perform the BCI control tasks for at least one year. .
- Ability to speak understandably or, if unable to speak understandably, a reliable means of yes/no communication.
- Life expectancy greater than 13 months.
- Chronic care environment within a three-hour drive of the study site or the ability to temporarily relocate to a residence within a three-hour drive of the study site.
- Willingness to remain available (geographically stable) for at least 13 months after enrollment, including maintenance of the evaluation schedule, frequent visits to the Investigator's office, and visits of Sponsor personnel to the subject's chronic care environment.
- Willingness to allow videotape recordings to be made of the surgical procedure (for training purposes) and portions of the Feasibility Evaluations.
- A stable psychosocial support system.
- Scalp devoid of any lesions or skin breakdown precluding surgery.
- Ability to provide voluntarily informed consent in accordance with Site institutional policies and willingness to release of Personal Health Information from the date of the injury or disease onset through the completion of the clinical Study.
- Availability of caregivers capable of providing the necessary daily care of the subject's skin and electrode externalization sites.
Exclusion Criteria:
- Presence of an implanted stimulator such as a pacemaker, spinal cord stimulator, cochlear implant, deep brain stimulator, vagus nerve stimulator, or defibrillator. (Implanted intrathecal pumps for pain or spasticity, cough implants, or diaphragmatic pacers are not excluded.)
- Any active infection(s) or unexplained fever.
- Active cancer within the one year prior to enrollment (other than adequately treated basal or squamous cell skin cancer).
- Uncontrolled insulin-dependent diabetes mellitus.
- Hydrocephalus requiring diversion of cerebrospinal fluid.
- Autonomic dysreflexia within three months prior to enrollment that required urgent evaluation and pharmacologic intervention prescribed by a physician.
- Seizure within 3 months prior to enrollment.
- Any medical condition expected to require routine MRI imaging or subjects with contraindication(s) to MRI.
- History of osteomyelitis or skin disorder that causes excessive skin sloughing, lesions or breakdown of the scalp.
- Chronic use of medications such as sedatives that may significantly retard motor coordination and cognitive ability.
- Chronic use of anticoagulant medications. (Subjects receiving prophylactic anticoagulation solely for the prevention of deep venous thrombosis are not excluded, but must be able to have their prophylactic anticoagulation suspended temporarily for the surgical procedure and immediate post-operative period.)
- Chronic use of steroids or immunosuppressant therapy.
- Active treatment for another serious medical, neurological or psychiatric disease or disorder that could seriously affect the subject's ability to undergo surgical implantation of the electrodes or participate in the testing sessions.
- Pregnant, lactating, or of childbearing age and not using adequate birth control.
- Active consumption of more than 1 alcoholic beverage per day.
- Suicide attempt within 12 months prior to enrollment.
- History of myocardial infarction or unstable cardiac arrhythmia.
- Enrollment in any other investigational study that may interfere with the time commitments required of this study.
- Subjects who are immunocompromised.
- Subjects who require ongoing diathermy or ultrasound treatments.
- Subjects with severe upper extremity joint contractures or Ashworth spasticity scores of 4 that would limit functional movements.
- Subjects who have contraindication(s) to CT.
- Subjects who are ventilator dependent. Subjects who are sometimes ventilator-assisted (for example, while sleeping) are not excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BCI and FES
Surgical implantation of the device and testing for 13 months with an optional 5 year extension study.
|
The intervention consists of surgical implantation of the device components, BCI and FES that will interface with computers that process and decode neural information, compute stimulation parameters, and control communication between the device components.
The device will be tested during research sessions spanning a 13-month period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-related adverse events
Time Frame: 13 months
|
Successful implantation of brain and extremity recording/stimulating electrodes for 1 year without explantation or device-related serious adverse events.
|
13 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Success rate of target acquisition of a cursor on a computer screen controlled by neural signals, using a standard center-out-center random target display.
Time Frame: 13 months
|
The participant will control the position of a cursor on a monitor using the recorded neural signals and attempt to move the cursor to the target.
|
13 months
|
Change in number of tasks performed as measured by the ADL Abilities Test.
Time Frame: 13 months
|
The participant will control the stimulated movement of their arm and hand using the recorded neural signals.
The participant will demonstrate the ability to perform some of the activities of daily living (ADLs) that are part of the ADL Abilities Test.
|
13 months
|
Change in number of objects successfully grasped and moved during a timed session, as measured by the Grasp Release Test.
Time Frame: 13 months
|
The participant will control the stimulated movement of their arm and hand using the recorded neural signals.
The participant will demonstrate the ability to grasp and move a series of objects that are part of the Grasp Release Test.
|
13 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jonathan Miller, University Hospitals Cleveland Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY20190226
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tetraplegia
-
Hospices Civils de LyonCompletedTetraplegia C5-C6 | Tetraplegia C6-C7France
-
Virginia Commonwealth UniversityMedical University of South Carolina; Eunice Kennedy Shriver National Institute...CompletedQuadriplegia/TetraplegiaUnited States
-
University of OsloOslo University Hospital; Sunnaas HospitalCompletedSpinal Cord Injured, TetraplegiaNorway
-
Virginia Commonwealth UniversityNational Institute on Disability, Independent Living, and Rehabilitation... and other collaboratorsRecruitingTetraplegia/TetraparesisUnited States
-
University Hospital, GrenobleRecruitingTraumatic Tetraplegia With Cervical Cord InjuryFrance
-
Hospices Civils de LyonRecruitingIndividuals With C6-C7 Tetraplegia (AIS A or B)France
-
VA Palo Alto Health Care SystemONWARD Medical, Inc.Not yet recruitingTetraplegiaUnited States
-
Sheba Medical CenterWithdrawnWheelchair Rugby Players With TetraplegiaIsrael
-
VA Palo Alto Health Care SystemCompletedParaplegia and TetraplegiaUnited States
-
Swiss Paraplegic Centre NottwilCompleted
Clinical Trials on BCI and FES
-
University of SheffieldMedical Research Council; Sheffield Teaching Hospitals NHS Foundation TrustCompleted
-
NHS Greater Glasgow and ClydeUniversity of GlasgowCompleted
-
NHS Greater Glasgow and ClydeUniversity of GlasgowCompleted
-
University of Wisconsin, MadisonAmerican Heart AssociationRecruiting
-
University of California, IrvineRecruiting
-
Louis Stokes VA Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS)CompletedStrokeUnited States
-
University of Texas at AustinRecruitingStroke | Healthy | Muscular Diseases | Movement Disorders | Motor Neuron Disease | Traumatic Brain Injury | Spinal Cord Injuries | Motor DisordersUnited States
-
Oregon Health and Science UniversityRecruitingAmyotrophic Lateral Sclerosis | Muscular Dystrophies | Spinal Cord Injuries | Multiple System Atrophy | Parkinson's Disease and Parkinsonism | Brain Tumor Adult | Locked-in Syndrome | Brainstem StrokeUnited States
-
Massachusetts General HospitalBrainCells Inc.CompletedMajor Depressive DisorderUnited States
-
US Department of Veterans AffairsNew York State Department of HealthCompletedALS (Amyotrophic Lateral Sclerosis)United States